Who
Timothy Schmid
EVP, WW Chair, MedTech
Company insider
Files Form 4 as: EVP, WW Chair, MedTech, Johnson & Johnson.
In numbers
- Trades disclosed
- 89
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $30.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 8 Feb 2024
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $1.5M11,070 at $131.94 | filing |
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $3.0M11,070 at $274.74 | filing |
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $3.4M22,527 at $151.41 | filing |
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,070 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —22,527 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $6.2M22,527 at $274.74 | filing |
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,070 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —22,527 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $1.5M11,070 at $131.94 | filing |
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $3.0M11,070 at $274.74 | filing |
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $3.4M22,527 at $151.41 | filing |
| 2 Sep 2026filed 4 Sep 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $6.2M22,527 at $274.74 | filing |
| 20 Feb 2026filed 23 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $325K1,322 at $245.66 | filing |
| 20 Feb 2026filed 23 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $325K1,322 at $245.66 | filing |
| 18 Feb 2026filed 18 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $3.3M13,625 at $244.20 | filing |
| 18 Feb 2026filed 18 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $1.2M8,998 at $129.51 | filing |
| 18 Feb 2026filed 18 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $2.2M8,998 at $244.53 | filing |
| 18 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —13,625 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,998 at $0.00 | filing |
| 18 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —13,625 at $0.00 | filing |
News
Johnson & Johnson's JNJ-6143 Shows Strong Early Efficacy In Pretreated Advanced Prostate CancerJNJ · rttnews.com · 25 Oct 2026Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ moleculeJNJ · prnewswire.com · 25 Oct 2026SBI Securities Co. Ltd. Acquires 10,021 Shares of Johnson & Johnson $JNJJNJ · dailypolitical.com · 25 Oct 2026
0 headlines in the last 90 days name Timothy Schmid; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.